Literature DB >> 28939150

Response to Osimertinib in Choroidal Metastases from EGFRmt T790M-Positive Non-Small Cell Lung Adenocarcinoma.

Filippo Gustavo Dall'Olio1, Celeste Ruatta2, Barbara Melotti3, Francesca Sperandi3, Antonio Pasquale Ciardella3, Andrea Ardizzoni2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28939150     DOI： 10.1016/j.jtho.2017.06.001

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  4 in total

1.  Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer.

Authors:  Matthew G Field; H Culver Boldt; Taher Abu Hejleh; Elaine M Binkley
Journal:  Am J Ophthalmol Case Rep       Date:  2022-03-01

2.  Treatment of Choroidal Metastasis from Epidermal Growth Factor Mutant Non-Small Cell Lung Cancer with First-line Osimertinib Therapy.

Authors:  Anderson N Vu; Urmi V Mehta; Paul Israelsen; Sai-Hong Ignatius Ou; Andrew W Browne
Journal:  J Ophthalmic Vis Res       Date:  2022-01-21

3.  Treating Choroidal Metastases and Improving Vision with Osimertinib in EGFR T790M-Mutated Lung Adenocarcinoma: A Case Report and Review of the Literature.

Authors:  Karim Keshwani; Kelsey A Roelofs; Gordon Hay; Rachel Lewis; Nick Plowman
Journal:  Ocul Oncol Pathol       Date:  2020-10-28

4.  Non-small cell lung cancer with iris metastasis controlled with osimertinib and monthly intravitreal bevacizumab.

Authors:  Margaret Wong; James H Frank; Carol L Shields
Journal:  Am J Ophthalmol Case Rep       Date:  2022-01-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.